Ivan Hyep Sells 1,882 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 1,882 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $18.15, for a total transaction of $34,158.30. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,638,193.25. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.55, for a total transaction of $330,097.25.
• On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total value of $10,980.75.

Bicara Therapeutics Price Performance

BCAX opened at $16.77 on Wednesday. The business has a 50 day moving average price of $17.50 and a two-hundred day moving average price of $14.82. The company has a market capitalization of $918.69 million, a price-to-earnings ratio of -7.49 and a beta of -0.79. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $19.71.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.12). Equities analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BCAX shares. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Finally, Wells Fargo & Company lifted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Institutional Trading of Bicara Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at $45,000. Legal & General Group Plc lifted its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares in the last quarter. Larson Financial Group LLC boosted its position in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.